Clinical Trial Update: Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial assessing ixazomib and rituximab after stem cell transplant in Mantle Cell Lymphoma in remission, spanning Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Rituximab (rituximab)
• ixazomib (ixazomib)

Snippet

Sponsor: Emory University | Conditions: Mantle Cell Lymphoma | Phase 1, Phase 2 | Status: UNKNOWN